<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32915">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678156</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-1403</org_study_id>
    <nct_id>NCT02678156</nct_id>
  </id_info>
  <brief_title>Assessment of the Performance of LYoplant® ONlay for Duraplasty</brief_title>
  <acronym>LYON</acronym>
  <official_title>Assessment of the Performance of LYoplant® ONlay for Duraplasty. A Non-interventional, Multi-centre Post Market Clinical Follow-up (PMCF) Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculap AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculap AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this Post Market Clinical Follow-up Study is to collect clinical data on the
      performance of Lyoplant® Onlay. To assess the performance of the product, various safety and
      efficacy parameters have been selected.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of re-operation because of Cerebrospinal Fluid leakage</measure>
    <time_frame>until discharge (approximately 1 week)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of re-operation because of Cerebrospinal Fluid leakage</measure>
    <time_frame>until follow-up (4 ± 2 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post operative complications</measure>
    <time_frame>until discharge (approximately 1 week, 4±2 months)</time_frame>
    <description>Cerebrospinal Fluid leakage, pseudomeningocele, fistulae, infection, meningitis and others</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cerebral reactions edema, soft tissue swelling, Cerebrospinal Fluid leakage</measure>
    <time_frame>until discharge (approximately 1 week, 4±2 months)</time_frame>
    <description>detected during routine post operative MRI / CT examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative handling of the device</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Intraoperative handling of the device using a questionnaire containing different dimension and a 5 point (1 = excellent, 5 = unacceptable) assessment level (Likert Scale). The following dimensions are assessed:
Ease of cutting
Needle penetration
Adaptation to the tissue
Suture retention strength
Onlay effect
Quality of sealing
Thickness
Tensile strength
Overall satisfaction</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Craniotomy</condition>
  <condition>Duraplasty</condition>
  <condition>Spinal Surgery</condition>
  <arm_group>
    <arm_group_label>LYoplant ONlay</arm_group_label>
    <description>Primary objective of the study is the generation of clinical data in patients receiving Lyoplant® Onlay for dura repair to assess its safety.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lyoplant Onlay</intervention_name>
    <arm_group_label>LYoplant ONlay</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing an elective cranial or spinal surgery, probably with the need of
             a duraplasty using Lyoplant® Onlay

          -  Written informed consent

          -  Life expectancy &gt; 6 months

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Active local or systemic infections

          -  Open cranial trauma

          -  Open spina bifida

          -  Known hypersensitivity to proteins of bovine origin

          -  Representation by a legal guardian or under involuntary commitment

          -  Pregnancy

          -  Participation in another clinical study

          -  Known primary immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Franziska Greifzu, Dr.</last_name>
    <phone>+497461--95-31272</phone>
    <email>franziska.greifzu@aesculap.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petra Baumann, Dr.</last_name>
    <phone>+49-7461-95-1646</phone>
    <email>petra.baumann@aesculap.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Bode, Dr.</last_name>
      <email>Frank.Bode@mail.klinikum-darmstadt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurochirurgie</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Stadie, PD Dr.</last_name>
      <phone>+4968411624442</phone>
      <email>Axel.Stadie@uks.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Idar-Oberstein</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>55743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen Tüttenberg, PD Dr.</last_name>
      <email>j.tuettenberg@io.shg-kliniken.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 6, 2016</lastchanged_date>
  <firstreceived_date>February 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dura mater substitute</keyword>
  <keyword>Graft</keyword>
  <keyword>Lyoplant</keyword>
  <keyword>Lyostypt</keyword>
  <keyword>Lyoplant onlay</keyword>
  <keyword>Xenograft</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
